Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Renews Deal with Proteome Sciences

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced Takeda Pharmaceuticals has extended a contract to use PS Biomarker Services for the development of mass spectrometry-based assays for disease-related proteins.

Financial and other terms of the deal were not disclosed.

In a statement, Proteome Sciences said it will apply its capabilities in the discovery and validation of peptide and protein biomarkers and in assay development for research covered by the deal.

The firms originally partnered in 2009 to use the PS Biomarker Services and Proteome Sciences' isobaric Tandem Mass Tags for a preclinical study.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.